Physician profile
Mona Sane
NPI 1861788564
$2,492.33
in general payments reported to CMS, 2019-2025
14 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $29.44 · 2021: $392 · 2022: $38.78 · 2023: $69.86 · 2024: $62.44 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $954.04 | 2021-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Alcon Vision LLC | $495.69 | 2019-2025 | Clareon Panoptix Pro, Wavelight Refractive Suite, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $169.47 | 2019-2025 | Tecnis Simplicity |
| Johnson & Johnson Vision Care, INC. | $129.65 | 2025 | |
| Avedro INC. | $126.30 | 2019 | |
| Dompe US, INC. | $124.99 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $115.70 | 2021 | |
| Hoffmann-La Roche Limited | $106.78 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.62 | 2019 | |
| Kala Pharmaceuticals, INC. | $54.19 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $53.50 | 2019-2020 | |
| Biotissue Holdings INC. | $50.65 | 2025 | |
| Harrow Eye, LLC | $20.05 | 2023 | Iheezo |
| Merck Sharp & Dohme LLC | $15.70 | 2023 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Sane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.